PPD Development, LP
PPD Development, LP
Explore linked clinical trials.27 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension | Difficult to Control Hypertension | Recruiting | Phase 2 | 2026-09-23 | NCT06343298 | |
| Belimumab With Rituximab for Primary Membranous Nephropathy | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, membranous glomerulonephritis, nephritis, nephrosis, nephrotic syndrome, urinary system disorder | Recruiting | Phase 2 | 2026-09-18 | NCT03949855 | |
| Efficacy of Tezepelumab in Peanut Oral Immunotherapy | Hypersensitivity, Immediate, Nut and Peanut Hypersensitivity, Peanut Hypersensitivity, food allergy, immune system disorder | Recruiting | Phase 2 | 2026-09-16 | NCT07015996 | |
| Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Recruiting | Phase 4 | 2026-09-16 | NCT06594068 | |
| Daratumumab in Primary Antiphospholipid Syndrome | antiphospholipid syndrome, autoimmune disease, immune system disorder | Recruiting | Phase 1 / Phase 2 | 2026-09-16 | NCT05671757 | |
| Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) | CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, relapsing-remitting multiple sclerosis | Recruiting | Phase 3 | 2026-09-16 | NCT04047628 | |
| The Anifrolumab PRIM Program | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Recruiting | Not stated | 2026-09-11 | NCT06795893 | |
| Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Recruiting | Not stated | 2026-09-02 | NCT06659029 | |
| Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Skin and Connective Tissue Diseases, Urogenital Diseases, autoimmune disease, connective tissue disorder, glomerulonephritis, immune system disorder, kidney disorder, lupus nephritis, nephritis, systemic lupus erythematosus, urinary system disorder | Recruiting | Phase 2 | 2026-08-24 | NCT07053800 | |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record) | Lung Injury, Respiration Disorders, acute lung injury, adult acute respiratory distress syndrome, lung disorder, respiratory system disorder | Recruiting | Phase 2 | 2026-07-31 | NCT06703073 | |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab | Lung Injury, Respiration Disorders, acute lung injury, adult acute respiratory distress syndrome, lung disorder, respiratory system disorder | Recruiting | Phase 2 | 2026-07-31 | NCT06701682 | |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart | Lung Injury, Respiration Disorders, acute lung injury, adult acute respiratory distress syndrome, lung disorder, respiratory system disorder | Recruiting | Phase 2 | 2026-07-31 | NCT06701669 | |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab | Lung Injury, Respiration Disorders, acute lung injury, adult acute respiratory distress syndrome, lung disorder, respiratory system disorder | Recruiting | Phase 2 | 2026-07-31 | NCT06701656 | |
| Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus) | AIDS, Blood-Borne Infections, Genital Diseases, HIV infectious disease, Infections, RNA Virus Infections, Slow Virus Diseases, Urogenital Diseases, immune system disorder, inborn error of immunity, infectious disease, lentivirus infection, sexually transmitted disease, uterine carcinosarcoma, viral infectious disease, viral sexually transmitted disease | Active, not recruiting | Phase 3 | 2026-07-30 | NCT06134362 | |
| A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, relapsing-remitting multiple sclerosis | Active, not recruiting | Phase 3 | 2026-07-15 | NCT05123703 | |
| A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure | Bacterial Infections and Mycoses, Borrelia infectious disease, Infections, Lyme disease, bacterial infectious disease, gram-negative bacterial infections, spirochaetales infections, tick-borne infectious disease, vector-borne disease | Active, not recruiting | Phase 2 | 2026-07-09 | NCT07562087 | |
| Department of Defense PTSD Adaptive Platform Trial - Intervention B - Vilazodone | Stress Disorders, Traumatic, acute stress disorder, post-traumatic stress disorder, psychiatric disorder | Not yet recruiting | Phase 2 | 2026-05-20 | NCT05948579 | |
| Carfilzomib and Belatacept for Desensitization | Highly Sensitized Prospective Kidney Transplant Recipients | Active, not recruiting | Phase 1 / Phase 2 | 2026-04-08 | NCT05017545 | |
| A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD | Pathologic Processes, Pathological Conditions, Signs and Symptoms, Respiration Disorders, Respiratory Aspiration, lung disorder, pulmonary arterial hypertension, pulmonary hypertension, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-04-01 | NCT04691154 | |
| Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, bone marrow disorder, bone marrow neoplasm, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Recruiting | Phase 3 | 2026-03-25 | NCT06093672 | |
| Phase 4 Paediatric Study to Evaluate Sonazoid Safety and Efficacy for Contrast-Enhanced Ultrasound Liver Imaging | Focal Liver Lesions | Recruiting | Phase 4 | 2026-03-04 | NCT06639828 | |
| A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Recruiting | Not stated | 2025-12-09 | NCT05721937 | |
| Vaginal Microbiome Exposure and Immune Responses in C-section Infants | Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Early phase 1 | 2025-11-05 | NCT03567707 | |
| Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 | Disease Attributes, Disease Progression, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 3 | 2025-10-01 | NCT04229979 | |
| Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications | Crohn disease, Digestive System Diseases, Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorder | Recruiting | Not stated | 2025-07-17 | NCT04846959 |